Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deglet Noor date derived polysaccharides (DP) are bioactive carbohydrate macromolecules extracted from the Deglet Noor variety of *Phoenix dactylifera* (date palm), a semi-dry date originating from Algeria. As a research-stage natural product, DP is investigated for its prebiotic and therapeutic potential, particularly in modulating the gut microbiome and enhancing intestinal barrier function. In preclinical models, it has demonstrated the ability to alleviate antibiotic-induced gut dysbiosis (such as amoxicillin-induced diarrhea) by increasing mucin-2 production, enhancing intestinal barrier integrity, and reducing pro-inflammatory cytokines. Additionally, research suggests potential applications in metabolic health, including blood glucose regulation and microbiota modulation in Type 1 diabetic models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Deglet Noor date derived polysaccharides.